PCI Biotech
US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants - Seite 3
For further information, please visit: www.pcibiotech.com
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions.
These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Lesen Sie auch
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.